New! View global litigation for patent families

WO1997039792A1 - Process for monitoring patients with chronic congestive heart failure - Google Patents

Process for monitoring patients with chronic congestive heart failure

Info

Publication number
WO1997039792A1
WO1997039792A1 PCT/US1997/006466 US9706466W WO1997039792A1 WO 1997039792 A1 WO1997039792 A1 WO 1997039792A1 US 9706466 W US9706466 W US 9706466W WO 1997039792 A1 WO1997039792 A1 WO 1997039792A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
values
water
calculated
chf
process
Prior art date
Application number
PCT/US1997/006466
Other languages
French (fr)
Inventor
Charles L. Feldman
Original Assignee
Zymed Medical Instrumentation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/08Arrangements or circuits for monitoring, protecting, controlling or indicating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/3627Heart stimulators for treating a mechanical deficiency of the heart, e.g. congestive heart failure or cardiomyopathy

Abstract

In a process (10) for monitoring patients with chronic congestive heart failure, a high frequency current is passed between electrodes (20) applied to two limbs of a patient. The current, voltage and phase angle between the measured current and voltage are measured (18) to enable the calculation of congestive heart failure (CHF) indicia values. The calculated CHF indicia values are then compared with baseline values established when the patient is in a known, stable condition. Intervention is initiated if the differences between the calculated CHF indicia values and the baseline values are outside of established tolerances. The CHF indicia values may include resistance, reactance, impedance, total body water and extracellular water. Moreover, the indicia values may include a figure of merit indicative of the hydration status of the patient.

Description

PRQOESS FOR MONITORING PATIENTS WITH CHRONIC CONGESTIVE HEART FAILURE

BACKGROUND OF THE INVENTION

Congestive heart failure (CHF) results when the heart is unable to contract with sufficient vigor to meet the body's need for oxygen. Under such circumstances, to increase cardiac output, autoregulatory mechanisms allow the filling pressure in the ventricles to increase, thus elongating myocardial fibers at the start of systole and increasing the strength of contraction. When the left and/or right filling pressures exceed approximately 15 mm Hg, blood components are forced out of the vasculature and into the interstitium, resulting in pulmonary edema (left heart failure) and/or peripheral edema and ascites (right heart failure). The end results is severe incapacitation and possibly death.

In a portion of the population with heart disease of many different etiologies - approximately 600,000 members of the U.S. population - the ability of the heart to meet the body's needs is marginal, resulting in chronic heart failure. For these patients, most of whom can be stabilized by medication and dietary restrictions and many of whom are quite elderly, minor variations in physical activity, emotional stress or non-compliance with diet or medication regimes can result in destabilization and episodes of acute heart failure requiring urgent hospitalization. Indeed, hospitalization for heart failure is the second most costly admitting diagnosis of the Medicare program. The most reliable existing method to monitor CHF is by direct measurement of pulmonary artery and central venous pressures through catheters inserted into the bloodstream. This method, though highly accurate, is clearly impractical outside of a hospital setting. Other methods include observation of the arterial pressure pattern (invasively or noninvasively) during a Valsalva maneuver, measurement of flow though the mitral annulus and in the pulmonary veins using doppler echocardiography, observation of neck vein distension, measurement of ankle dimensions and careful tracking of body weight. The first two, though reasonably accurate, require considerable equipment and trained personnel while the last three are quite unreliable for a variety of reasons.

Subramanyan, et al. and others have shown that both the resistive and reactive components of the body's impedance to the flow of relatively high frequency (50 kHz) electrical current is sensitive to the amount of fluid retained by a patient with CHF. As the CHF resolves, resistance and reactance both increase as does the electrical phase angle (tan'1 reactance/resistance). See Subramanyan, et al., Total Body Water in Congestive Heart Failure. Jour. Asso. Phys. Ind., Vol. 28, September, 1980, pages 257-262. Others, including

Lukaski & Bolonchuk, have derived relationships between the components of the body's electrical impedance at either 50 kHz or 1000 Hz and either total body water or extracellular fluid. See Lukaski, et al., Estimation of Body Fluid Volumes Using Tetrapolar Bioelectrical Impedance Measurements. Aviation Space and Environmental Medicine; 1988; 59: 1163-1169.

There remains a need, however, for a practical and reliable method for monitoring the status of CHF patients outside of a hospital setting. Such a monitoring method may build on the observations of Subramanyan et al. and Lukaski & Bolonchuk with the goal of intervening before the onset of acute CHF. It would be most desirable to provide a simple way of detecting increases in body water of patients with CHF before hospitalization is necessary and permitting adjustments in medication and/or diet in time to prevent an episode of acute heart failure. The present invention fulfills these needs and provides other related advantages.

SUMMARY OF THE INVENTION

The present invention resides in an "early warning" monitoring system for determining changes in the status of patients with chronic congestive heart failure (CHF), with the goal of intervening before the onset of acute congestive heart failure. In accordance with the present invention, a process for monitoring patients with chronic congestive heart failure comprises the steps of applying electrodes to two points on the body, passing a current at one or more high frequencies between the electrodes, and then measuring the current (I) and voltage (V). Congestive heart failure (CHF) indicia values are calculated based on the measured current (I) and voltage

5 (V), and the calculated CHF indicia values are then compared with baseline values established when the patient is in a known, stable condition, to determine if differences therebetween are within established tolerances.

In a preferred form of the invention the process comprises the steps of applying the electrodes to two limbs of a patient and then passing a i o high frequency current between the electrodes. Current (I), voltage (V) and phase angle (+) are measured, and then congestive heart failure (CHF) indicia values, including resistance (R) and reactance (Zc), are calculated. The calculated CHF indicia values are then compared with baseline values, and intervention is initiated when the differences between the calculated CHF

15 indicia values and the baseline values are outside of established tolerances.

The process is repeated at an interval determined by whether or not intervention was required. The calculated CHF indicia values may include, in addition, impedance (Z).

A decrease in the phase angle (f) or any of the calculated CHF

20 indicia values of resistance (R), reactance (Zc) or impedance (Z), is an indicator of the need to initiate intervention. The tolerances from baseline values for the calculated CHF indicia values are on the order of five percent (5%) for resistance (R) and impedance (Z), ten percent (10%) for reactance (Zc), and twenty percent (20%) for phase angle (f).

25 The calculated CHF indicia values may also include total body water (TBW) and extracellular water (ECW). An increase in the calculated total body water (TBW) or extracellular water (ECW) is an indicator of the need to initiate intervention. The tolerances from baseline values are on the order of five percent (5%) for total body water (TBW) and extracellular water (ECW).

30 Total body water (TBW) may be calculated utilizing the formula:

TBW = .377 Ht2/R + .14 Wt - .08 Age + 2.9 Gender + 4.65 (Where Gender = 1 for male and 0 for female). Extracellular water (ECW) may be calculated utilizing the formula:

ECW = .189 Ht2/R + .52 Wt - .0002Ht2/Zc + 1.03.

The calculated CHF indicia values may further include a figure of merit which is indicative of the hydration status of the patient. By way of example, the figure of merit may be derived from the ratio of extracellular water (ECW) over fat-free mass (FFM). Fat-free mass (FFM) may be calculated utilizing the formula:

FFM = - 15.26 - .775(Ht2/R) + .146 Wt + .185 Zc. Intervention is indicated when the ratio of extracellular water (ECW) to fat-free mass (FFM) is greater than approximately 0.30. Moreover, an increase in the figure of merit on the order of one percent (1 %) is an additional indicator of the need to initiate intervention.

Other features and advantages of the present invention will become apparent from the following more detailed description, taken in conjunction with the accompanying drawings which illustrate, by way of example, the principles of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings illustrate the invention. In such drawings:

FIGURE 1 is the first of a two-part flow chart illustrating a process for monitoring patients with chronic congestive heart failure embodying the present invention; and

FIGURE 2 is the second of the two-part flow chart illustrating the process of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

As shown in the drawings for purposes of illustration, the present invention is concerned with a novel process for monitoring patients with congestive heart failure, generally indicated in FIGS. 1 and 2 by the reference number 10. In accordance with the present invention, the process 10 comprises, generally, the steps of applying electrodes to two points on the body of a patient and, while passing a current at one or more high frequencies between the electrodes, measuring the current (I) and voltage (V). Congestive heart failure (CHF) indicia values are then calculated based on the measured current (I) and voltage (V), which are compared with baseline values to determine if differences therebetween are within established tolerances. If those differences are outside of the established tolerances, intervention is initiated in accordance with sound medical practice. Thus, the process 10 of the present invention provides an "early warning" monitoring system for determining changes in the status of patients with chronic congestive heart failure with the goal of intervening before the onset of acute CHF.

The process 10 of the present invention involves the tracking of total body impedance (Z), resistance (R), reactance (Zc) and phase angle (<r) in an abulatory patient with chronic congestive heart failure (CHF), and uses the decrease of any or all of these "indicia values" as predictors of the onset of acute CHF. The measurement can be made using a commercial device, such as that manufactured by RJL Systems of Clinton Twp., Ml, to measure body composition, or a similar device designed for this purpose. Significant intra-patient changes over time in the values of these parameters (for example five percent or more) would be viewed as indicators of a deteriorating physical condition. The electrodes may be placed on any two points on the body, but preferably are positioned on either the ipsilateral wrist and ankle or on the contralateral wrist and ankle as described in Subramanyan, et al., Total Body Water in Congestive Heart Failure. Jour. Asso. Phys. Ind., Vol. 28, September,

1980, pages 257-262. Measurements are typically made at a high frequency

(above 20 kHz - largely sensitive to total body water, or below 20 kHz - sensitive primarily to volume of extracellular fluid), or multiple frequencies.

The process 10 of the present invention also includes utilizing the techniques described above applied to separate portions of the body of the patient to separately track peripheral and pulmonary edema. For example, measuring and tracking ankle-to-ankle impedance (Z) and its components would highlight changes in peripheral fluid, primarily indicative of right heart failure. Wrist-to-wrist impedance (Z) components would be more indicative of changes in lung fluid and left heart failure. Changes in any of these component impedance values would be used as an indicator of instability and suggest changes in therapeutic regimen.

Combining the measurements obtained above with body dimensions and body weight in formulas such as those described by Lukaski, H.C. & Bolonchuk, W.W. Estimation of Bodv Fluid Volumes Using Tetrapolar Bioelectrical Impedance Measurements. Aviation Space and Environmental o Medicine; 1988; 59; 1163-1169 enables estimates to be obtained of total body water (TBW) and intracellular and extracellular water (ECW). Increases in the estimated amount of total or extracellular water of approximately one half to one liter from its baseline value would be used as an indicator progressive heart failure and for therapeutic intervention. Moreover, combining estimates 5 of total and extracellular water with estimates of body cell mass into a "figure of merit" indicative of the hydration status of the patient may be advantageously accomplished in accordance with the process 10 of the present invention. Changes in the "figure of merit" would be used as an indicator of worsening condition of the CHF patient. Typical figures of merit o would include the ratio of extracellular fluid (ECW)/fat-free mass (FFM), or the ratio of extracellular water (ECW)/total body weight. An increases in the figure of merit of approximately one percent (1%) would be used as an indicator of worsening condition. Moreover, certain figures of merit, per se, rather than their change may be utilized as an indicator of congestive heart failure. For 5 example, when the ratio of extracellular water (ECW)/fat-free mass (FFM) is greater than approximately 0.30, it may be assumed that the patient is in congestive heart failure.

With reference specifically to FIG. 1 , the process 10 begins by applying clinical criteria to evaluate the risk of acute heart failure (block 12). 0 Factors to be evaluated are the patient's history of hospitalization for congestive heart failure (CHF), left ventricular ejection fraction (EF - the fraction of the left ventricle that is emptied in each cardiac contraction), and typical signs of CHF including neck vein distention, shortness of breath and swelling of the extremities. The patient is next evaluated to determine whether or not he or she may be classified as a high risk (block 14). High risk patients are those who have been hospitalized for CHF within the last three months, those who have been hospitalized for CHF within the last year and show new neck vein distention, those who have shortness of breath at rest or with minimal exertion, and/or those with an ejection fraction (EF) less than forty percent, for example. If the patient is not classified as a high risk, the physician may reevaluate the diagnosis as appropriate, for example, every three months or so (block 16). If, on the other hand, the patient is evaluated to be a high risk, then the bioelectric impedance analysis of the present invention is conducted to enable the health care provider to determine the patient's congestive heart failure (CHF) indicia values for purposes of comparing those values with baseline values established when the patient is in a known stable condition (block 18).

In the preferred embodiment, two electrodes are attached to each of two limbs (block 20). The two more distal electrodes (i.e., hand and foot) are used for injecting current (I) while the two more proximal electrodes (i.e., wrist and ankle) are used for measuring voltage (V). If, however, the electrodes have sufficient surface area so that the contact impedance is very low compared to the impedance (Z) of the body (i.e., «500Ω), a single electrode on each of the two limbs can be used for both current injection and voltage measurement. Any pair of limbs may be used (right arm to left leg, right arm to left arm, etc.), or multiple pairs can be used and results calculated pair-by-pair. In the preferred embodiment, the electrodes are attached to the lower left extremity and the upper right extremity.

Once the electrodes have been properly attached to the patient, a high frequency current is passed between the electrodes (block 22). A typical (preferred) current is 800μamp at 50 kHz. A current of up to 5 ma could be used as well as any single frequency from 10 kHz to 100 kHz.

Alternatively, two different frequencies, one below 10 kHz (for example 1 kHz) and one above (for example 100 kHz) could be utilized. As the high frequency current is passed between the electrodes, the current (I) is measured (block 24) as well as the voltage (V) and phase angle (Φ) between the measured current (I) and voltage (V) (block 26). In this regard, the voltage (V) and current (I) can be measured with any conventional technique, analog or digital. As is known by those in the art, the delay between voltage and current in zero crossing (current lags voltage) bears the same relation to the waveform period as the phase angle (Φ) does to 360°. In other words, the phase angle (+) = 360 (t/T), where t„ is the time by which current (I) lags voltage (V), and (T) is the waveform period (the inverse of frequency). For a 50 kHz current, T = o 1 /50.000 = 20μ seconds.

Having thus measured the current (I), voltage (V) and the phase angle {+), congestive heart failure (CHF) indicia values may then be calculated (blocks 28, 30 and 32). As illustrated in block 28, the first indicia values calculated include impedance (Z), resistance (R) and reactance (Zc). 5 Impedance (Z) is the rms voltage divided rms current. Resistance (R) is the impedance (Z) multiplied by the cosine of the phase angle (*), or R = Z cos Ψ. Reactance (Zc) is the capacitive component of impedance (Z) and is determined by multiplying the impedance (Z) by the sine of the phase angle (+), or Zc = Z sin i 0 As illustrated in block 30, the patient's total body water (TBW), extracellular water (ECW) and fat-free mass (FFM) may also be calculated to provide CHF indicia values. Total body water (TBW) and extracellular water (ECW) can be calculated from the formulas of Lukaski H.C. & Bolonchuk W.W. Estimation of Bodv Fluid Volumes Using Tetrapolar Bioelectrical 5 Impedance Measurements. Aviation Space and Environmental Medicine,

1988; 59; 1163-1169. These formulas are:

TBW = .377 Ht2/R + .14 Wt - .08 Age + 2.9 Gender + 4.65

(Where Gender = 1 for male and 0 for female), and

ECW = .189 Ht2/R + .52 Wt - .0002Ht2/Zc + 1.03 o wherein Ht = the height of the patient (cm) and Wt = the weight of the patient

(Kg). Fat-free mass (FFM) can be calculated from the formula provided in Huges, V.A., and Evans W.J. Assessment of Fat-Free Mass in an Older Population Using Bioelectric Impedance. Fed Proc 1987; 46 (Abstract), as follows:

FFM = - 15.26 - .775(Ht2/R) + .146 Wt + .185 Z, Other versions of these formulas are available as are formulae for two frequency analyses.

Block 32 illustrates deriving a "figure of merit" from the ratio of extracellular water (ECW) over fat-free mass (FFM).

When beginning the monitoring program, it is necessary to establish baseline values for the calculated CHF indicia (blocks 28-32). The baseline values are preferably measured when the patient is in a known, stable condition, such as when discharged from the hospital and/or entered into the monitoring program. If it is the baseline values that are being established (block 34), they are stored (block 36) for further reference. The stored baseline values will typically include the weight (Wt) of the patient, the calculated impedance (Z), resistance (R), reactance (Zc), phase angle (*), total body water (TBW), extracellular water (ECW), fat-free mass (FFM), and the ratio of extracellular water to fat-free mass (ECW/FFM). Once the baseline values have been established and stored (block 36), there is a delay (block 38) before repeating the bioelectric impedance analysis (18). The preferred delay before repeating the measurements is one to two weeks.

Subsequent analyses (18) follow the same process steps 20-32 as discussed above. However, since the baseline values have already been established and stored (34, 36) the newly calculated indicia values (28, 30 and 32) are then compared with the previously established baseline values (block 40) to determine if differences therebetween are within established tolerances

(block 42). In the preferred embodiment of the invention, a decrease in the phase angle (Ψ) or any of the calculated CHF indicia values of resistance (R), reactance (ZJ or impedance (Z), is an indicator of the need to initiate intervention. The tolerances from baseline values are on the order of five percent (5%) for resistance (R) and impedance (Z), ten percent (10%) for reactance (Zc), and twenty percent (20%) for phase angle (+). An increase in the calculated total body water (TBW) or extracellular water (ECW) is an indicator of the need to initiate intervention. The tolerances from baseline values for such calculated CHF indicia values are on the order of five percent

(5%) for both the total body water (TBW) and extracellular water (ECW) calculations. With regard to the figure of merit derived from the ratio of extracellular water (ECW) over fat-free mass (FFM), intervention is indicated when such ratio is greater than approximately 0.30 and/or there is an increase in the figure of merit on the order of one percent (1%).

If the calculated CHF indicia values are within established tolerances, then there is simply a delay (38) before repeating measurements. In particular, for those patients these measurements fall within tolerances, the preferred delay before repeating the measurements is one to two weeks.

Patients whose clinical history so indicated could be monitored either less frequently or more frequently.

For those patients whose measurements do not fall within tolerances, intervention is indicated (block 44). Interventions are based on medical judgment and form no part of the present invention. They might include counseling to reduce the amount of salt in the diet or reduce activity.

The use of diuretics and/or angiotensin converting enzyme inhibitors could be increased. In severe cases, intravenous diuretics could be started as could intravenous agents to increase the pumping action of the heart (inotropes such as dobutamine), or the patient could be advised to seek hospitalization.

Patients undergoing stabilization through therapeutic interventions should be monitored more frequently, thus reducing the delay before repeating measurements (38) to a day or two. Although a particular embodiment of the invention has been described in detail for purposes of illustration, various modifications may be made without departing from the spirit and scope of the invention.

Accordingly, the invention is not to be limited, except as by the appended claims.

Claims

I Claim:
1. A process for monitoring patients with chronic congestive heart failure, comprising the steps of: applying electrodes to two limbs of a patient; passing a high frequency current between the electrodes; measuring the current (I), voltage (V) and phase angle (f) between the voltage (V) and the measured current (I); calculating congestive heart failure (CHF) indicia values based on the measured current (I), voltage (V) and phase angle (♦); and comparing the calculated CHF indicia values with baseline values to determine if differences therebetween are within established tolerances.
2. The process of claim 1 , including the step of establishing the baseline values when the patient is in a known, stable condition.
3. The process of claim 2, including the step of initiating intervention when, during the comparing step, the differences between the calculated CHF indicia values and the baseline values are outside of established tolerances.
4. The process of claim 3, including the step of repeating the process for monitoring patients with chronic congestive heart failure at an interval determined by whether or not intervention was required.
5. The process of claim 3, wherein the calculated CHF indicia values include resistance (R) and reactance (Zc).
6. The process of claim 5, wherein the calculated CHF indicia values include impedance (Z).
7. The process of claim 6, wherein a decrease in the phase angle (ή or any ofthe calculated CHF indicia values of resistance (R), reactance (ZJ or impedance (Z), is an indicator of the need to initiate intervention.
8. The process of claim 7, wherein the tolerances from baseline values for the calculated CHF indicia values are on the order of five percent (5%) for resistance (R) and impedance (Z), ten percent (10%) for reactance (Zc), and twenty percent (20%) for phase angle (Ψ).
9. The process of claim 5, wherein the calculated CHF indicia values include total body water (TBW) and extracellular water (ECW).
10. The process of claim 9, wherein total body water (TBW) is calculated utilizing the formula:
TBW = .377 Ht2/R + .14 Wt - .08 Age + 2.9 Gender + 4.65 (Where Gender = 1 for male and 0 for female), and wherein extracellular water (ECW) is calculated utilizing the formula: ECW = .189 Ht2/R + .52 Wt - .0002Ht2/Zc + 1.03, wherein Ht = the height of the patient and Wt = the weight of the patient.
11. The process of claim 9, wherein an increase in the calculated total body water (TBW) or extracellular water (ECW) is an indicator of the need to initiate intervention.
12. The process of claim 11 , wherein the tolerances from baseline values for the calculated CHF indicia values are on the order of five percent (5%) for total body water (TBW) and extracellular water (ECW).
13. The process of claim 5, wherein the calculated CHF indicia values include a figure of merit indicative of the hydration status of the patient.
14. The process of claim 13, wherein the figure of merit is derived from the ratio of extracellular water (ECW) over fat-free mass (FFM).
15. The process of claim 14, wherein extracellular water (ECW) is calculated using the formula:
ECW = .189 Ht2/R + .52 Wt - .0002Ht2/Zc + 1.03, and wherein fat-free mass (FFM) is calculated utilizing the formula: FFM = - 15.26 - ,775(Ht2/R) + .146 Wt + .185 Zc, wherein Ht = the height of the patient and Wt = the weight of the patient.
16. The process of claim 14, wherein intervention is indicated when the ratio of extracellular water (ECW) to fat-free mass (FFM) is greater than approximately 0.30.
17. The process of claim 14, wherein an increase in the figure of merit on the order of one percent (1%) is an indicator of the need to initiate intervention.
18. A process for monitoring patients with chronic congestive heart failure, comprising the steps of: applying electrodes to two points on the body of a patient; passing a current at one or more high frequencies between the electrodes; measuring the current (I) and voltage (V) at each frequency; calculating congestive heart failure (CHF) indicia values based on the measured current(s) (I) and voltage(s) (V); and comparing the calculated CHF indicia values with baseline values to determine if differences therebetween are within established tolerances.
19. The process of claim 18, including the steps of establishing baseline values determined when the patient is in a known, stable condition, initiating intervention when, during the comparing step, the differences between the calculated CHF indicia values and the baseline values are outside of established tolerances, and repeating the process for monitoring patients with chronic congestive heart failure at an interval determined by whether or not intervention was required.
20. The process of claim 19, wherein the calculated CHF indicia values include total body water (TBW) and extracellular water (ECW), and wherein an increase in the calculated total body water (TBW) or extracellular water (ECW) is an indicator of the need to initiate intervention.
21. The process of claim 20, wherein the tolerances from baseline values for the calculated CHF indicia values are on the order of five percent (5%) for total body water (TBW) and extracellular water (ECW).
22. The process of claim 20, wherein the calculated CHF indicia values include a figure of merit, derived from the ratio of extracellular water (ECW) over fat-free mass (FFM), that is indicative of the hydration status of the patient.
23. The process of claim 22, wherein intervention is indicated when the ratio of extracellular water (ECW) to fat-free mass (FFM) is greater than approximately 0.30, or there is an increase in the figure of merit on the order of one percent (1%).
24. The process of claim 19, including the step of measuring the phase angle (+) between the measured current (I) and voltage (V) at each frequency, and wherein the calculated CHF indicia values include resistance (R), reactance (Zc), and impedance (Z).
25. The process of claim 24, wherein a decrease in the phase angle (T) or any of the calculated CHF indicia values of resistance (R), reactance (Zc) or impedance (Z), is an indicator of the need to initiate intervention.
26. The process of claim 24, wherein the tolerances from baseline values for the calculated CHF indicia values are on the order of five percent (5%) for resistance (R) and impedance (Z), ten percent (10%) for reactance (ZJ, and twenty percent (20%) for phase angle (4-).
27. A process for monitoring patients with chronic congestive heart failure, comprising the steps of: applying electrodes to two limbs of a patient; passing a high frequency current between the electrodes; 5 measuring the current (I), voltage (V) and phase angle (i) between the voltage (V) and the measured current (I); calculating congestive heart failure (CHF) indicia values, including resistance (R) and reactance (Zc), based on the measured current (I), voltage (V) and phase angle (i); l o comparing the calculated CHF indicia values with baseline values to determine if differences therebetween are within established tolerances; initiating intervention when, during the comparing step, the differences between the calculated CHF indicia values and the baseline values are outside of established tolerances; and 15 repeating the process for monitoring patients with chronic congestive heart failure at an interval determined by whether or not intervention was required.
28. The process of claim 27, including the step of establishing the baseline values when the patient is in a known, stable condition.
29. The process of claim 28, wherein the calculated CHF indicia values include impedance (Z), and wherein a decrease in the phase angle (♦) or any of the calculated CHF indicia values of resistance (R), reactance (Zc) or impedance (Z), is an indicator of the need to initiate intervention.
30. The process of claim 29, wherein the tolerances from baseline values for the calculated CHF indicia values are on the order of five percent (5%) for resistance (R) and impedance (Z), ten percent (10%) for reactance (Zc), and twenty percent (20%) for phase angle (+).
31. The process of claim 27, wherein the calculated CHF indicia values include total body water (TBW) and extracellular water (ECW), and wherein an increase in the calculated total body water (TBW) or extracellular water (ECW) is an indicator of the need to initiate intervention.
32. The process of claim 31 , wherein total body water (TBW) is calculated utilizing the formula:
TBW = .377 Ht2/R + .14 Wt - .08 Age + 2.9 Gender + 4.65 (Where Gender = 1 for male and 0 for female), and wherein extracellular water (ECW) is calculated utilizing the formula: ECW = .189 Ht2/R + .52 Wt - .0002Ht2/Zc + 1.03, wherein Ht = the height of the patient and Wt = the weight of the patient.
33. The process of claim 31 , wherein the tolerances from baseline values for the calculated CHF indicia values are on the order of five percent (5%) for total body water (TBW) and extracellular water (ECW).
34. The process of claim 27, wherein the calculated CHF indicia values include a figure of merit indicative of the hydration status of the patient.
35. The process of claim 34, wherein the figure of merit is derived from the ratio of extracellular water (ECW) over fat-free mass (FFM), wherein inteπ/ention is indicated when the ratio of extracellular water (ECW) to fat-free mass (FFM) is greater than approximately 0.30, and wherein an increase in the figure of merit on the order of one percent (1%) is an indicator of the need to initiate intervention.
36. The process of claim 35, wherein extracellular water (ECW) is calculated using the formula: ECW = .189 Ht2/R + .52 Wt - .0002Ht2/Zc + 1.03, and wherein fat-free mass (FFM) is calculated utilizing the formula: FFM = - 15.26 - .775(Ht2/R) + .146 Wt + .185 Zc, wherein Ht = the height of the patient and Wt = the weight of the patient.
PCT/US1997/006466 1996-04-23 1997-04-22 Process for monitoring patients with chronic congestive heart failure WO1997039792A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US1601596 true 1996-04-23 1996-04-23
US60/016,015 1996-04-23

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP53819597A JP3325273B2 (en) 1996-04-23 1997-04-22 Monitor patients suffering from chronic congestive heart failure
EP19970922343 EP0921842A4 (en) 1996-04-23 1997-04-22 Process for monitoring patients with chronic congestive heart failure
CA 2251718 CA2251718C (en) 1996-04-23 1997-04-22 Process for monitoring patients with chronic congestive heart failure

Publications (1)

Publication Number Publication Date
WO1997039792A1 true true WO1997039792A1 (en) 1997-10-30

Family

ID=21774907

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/006466 WO1997039792A1 (en) 1996-04-23 1997-04-22 Process for monitoring patients with chronic congestive heart failure

Country Status (4)

Country Link
EP (1) EP0921842A4 (en)
JP (1) JP3325273B2 (en)
CA (1) CA2251718C (en)
WO (1) WO1997039792A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1102196A3 (en) * 1999-11-16 2002-05-15 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring congestive heart failure and outcomes therof
US6440066B1 (en) 1999-11-16 2002-08-27 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for ordering and prioritizing multiple health disorders to identify an index disorder
US6478737B2 (en) 1999-06-03 2002-11-12 Cardiac Intelligence Corporation System and method for analyzing normalized patient voice feedback an automated collection and analysis patient care system
US6607485B2 (en) 1999-06-03 2003-08-19 Cardiac Intelligence Corporation Computer readable storage medium containing code for automated collection and analysis of patient information retrieved from an implantable medical device for remote patient care
US6694186B2 (en) 1999-11-16 2004-02-17 Cardiac Intelligence Corporation Automated collection and analysis patient care system for managing the pathophysiological outcomes of atrial fibrillation
US6827690B2 (en) 1999-11-16 2004-12-07 Cardiac Intelligence Corporation System and method for providing diagnosis and monitoring of myocardial ischemia for use in automated patient care
US6852080B2 (en) 1999-06-03 2005-02-08 Cardiac Intelligence Corporation System and method for providing feedback to an individual patient for automated remote patient care
US6866629B2 (en) 1999-07-26 2005-03-15 Cardiac Intelligence Corporation Automated system and method for establishing a patient status reference baseline
US6887201B2 (en) 1999-07-26 2005-05-03 Cardiac Intelligence Corporation System and method for determining a reference baseline of regularly retrieved patient information for automated remote patient care
US6974413B2 (en) 1999-06-03 2005-12-13 Cardiac Intelligence Corporation System and method for analyzing patient information for use in automated patient care
US7134996B2 (en) 1999-06-03 2006-11-14 Cardiac Intelligence Corporation System and method for collection and analysis of patient information for automated remote patient care
US7386345B2 (en) 2005-01-27 2008-06-10 Cardiac Pacemakers, Inc. Apparatus and method for temporary treatment of acute heart failure decompensation
US8888710B2 (en) 2004-02-19 2014-11-18 Cardiac Pacemakers, Inc. System and method for assessing cardiac performance through cardiac vibration monitoring
US8942794B2 (en) 1999-11-16 2015-01-27 Cardiac Pacemakers, Inc. System and method for prioritizing medical conditions

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7127290B2 (en) * 1999-10-01 2006-10-24 Cardiac Pacemakers, Inc. Cardiac rhythm management systems and methods predicting congestive heart failure status
JP5829123B2 (en) * 2008-09-22 2015-12-09 チーター メディカル インコーポレイテッド System and method for determining the blood flow
KR101823496B1 (en) 2016-08-22 2018-01-31 조선대학교산학협력단 Wearable device for measuring edema index and method of measuring edema index using thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4899758A (en) * 1986-01-31 1990-02-13 Regents Of The University Of Minnesota Method and apparatus for monitoring and diagnosing hypertension and congestive heart failure
US5560368A (en) * 1994-11-15 1996-10-01 Berger; Ronald D. Methodology for automated QT variability measurement
US5584868A (en) * 1992-11-03 1996-12-17 Cardiac Pacemakers, Inc. Cardiac stimulating apparatus and method for heart failure therapy

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4899758A (en) * 1986-01-31 1990-02-13 Regents Of The University Of Minnesota Method and apparatus for monitoring and diagnosing hypertension and congestive heart failure
US5584868A (en) * 1992-11-03 1996-12-17 Cardiac Pacemakers, Inc. Cardiac stimulating apparatus and method for heart failure therapy
US5560368A (en) * 1994-11-15 1996-10-01 Berger; Ronald D. Methodology for automated QT variability measurement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0921842A4 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6926668B2 (en) 1999-06-03 2005-08-09 Cardiac Intelligence Corporation System and method for analyzing normalized patient voice feedback in an automated collection and analysis patient care system
US9149237B2 (en) 1999-06-03 2015-10-06 Cardiac Pacemakers, Inc. System and method for evaluating a patient status for use in heart failure assessment
US6478737B2 (en) 1999-06-03 2002-11-12 Cardiac Intelligence Corporation System and method for analyzing normalized patient voice feedback an automated collection and analysis patient care system
US6607485B2 (en) 1999-06-03 2003-08-19 Cardiac Intelligence Corporation Computer readable storage medium containing code for automated collection and analysis of patient information retrieved from an implantable medical device for remote patient care
US7070562B2 (en) 1999-06-03 2006-07-04 Cardiac Intelligence Corporation System and method for providing tiered patient feedback for use in automated patient care
US6997873B2 (en) 1999-06-03 2006-02-14 Cardiac Intelligence Corporation System and method for processing normalized voice feedback for use in automated patient care
US6705991B2 (en) 1999-06-03 2004-03-16 Cardiac Intelligence Corporation System and method for providing patient status diagnosis for use in automated patient care
US9186061B2 (en) 1999-06-03 2015-11-17 Cardiac Pacemakers, Inc. System and method for evaluating a patient status for use in heart failure assessment
US9526456B2 (en) 1999-06-03 2016-12-27 Cardiac Pacemakers, Inc. System and method for evaluating a patient status for use in heart failure assessment
US7104955B2 (en) 1999-06-03 2006-09-12 Cardiac Intelligence Corporation System and method for collection and analysis of regularly retrieved patient information for automated remote patient care
US7144369B2 (en) 1999-06-03 2006-12-05 Cardiac Intelligence Corporation System and method for providing collection and analysis of patient information for use in automated patient care
US6852080B2 (en) 1999-06-03 2005-02-08 Cardiac Intelligence Corporation System and method for providing feedback to an individual patient for automated remote patient care
US6860897B2 (en) 1999-06-03 2005-03-01 Cardiac Intelligence Corporation System and method for providing feedback to an individual patient for automated remote patient care
US6908431B2 (en) 1999-06-03 2005-06-21 Cardiac Intelligence Corporation System and method for providing feedback to an individual patient for automated remote patient care
US7134996B2 (en) 1999-06-03 2006-11-14 Cardiac Intelligence Corporation System and method for collection and analysis of patient information for automated remote patient care
US6905463B2 (en) 1999-06-03 2005-06-14 Cardiac Intelligence Corporation System and method for providing feedback to an individual patient for automated remote patient care
US6974413B2 (en) 1999-06-03 2005-12-13 Cardiac Intelligence Corporation System and method for analyzing patient information for use in automated patient care
US6893397B2 (en) 1999-07-26 2005-05-17 Cardiac Intelligence Corporation System and method for determining a reference baseline of patient information for automated remote patient care
US6887201B2 (en) 1999-07-26 2005-05-03 Cardiac Intelligence Corporation System and method for determining a reference baseline of regularly retrieved patient information for automated remote patient care
US6866629B2 (en) 1999-07-26 2005-03-15 Cardiac Intelligence Corporation Automated system and method for establishing a patient status reference baseline
US7248916B2 (en) 1999-07-26 2007-07-24 Cardiac Intelligence Corporation Automated system and method for establishing a patient status reference baseline
US8888698B2 (en) 1999-07-26 2014-11-18 Cardiac Pacemakers, Inc. System and method for determining a reference baseline for use in heart failure assessment
US6945934B2 (en) 1999-07-26 2005-09-20 Cardiac Intelligence Corporation System and method for determining a reference baseline record for use in automated patient care
US9610012B2 (en) 1999-07-26 2017-04-04 Cardiac Pacemakers, Inc. System and apparatus for providing baseline data for automated patient management
US6960167B2 (en) 1999-07-26 2005-11-01 Cardiac Intelligence Corporation System and method for patient monitoring using a reference baseline for use in automated patient care
EP1102196A3 (en) * 1999-11-16 2002-05-15 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for diagnosing and monitoring congestive heart failure and outcomes therof
US6904312B2 (en) 1999-11-16 2005-06-07 Cardiac Intelligence Corporation System and method for diagnosing and monitoring outcomes of atrial fibrillation for automated remote patient care
US6951539B2 (en) 1999-11-16 2005-10-04 Cardiac Intelligence Corporation System and method for ordering and prioritizing multiple health disorders for automated remote patient care
US6913577B2 (en) 1999-11-16 2005-07-05 Cardiac Intelligence Corporation System and method for diagnosing and monitoring myocardial ischemia for automated remote patient care
US6908437B2 (en) 1999-11-16 2005-06-21 Cardiac Intelligence Corporation System and method for diagnosing and monitoring congestive heart failure for automated remote patient care
US6834203B2 (en) 1999-11-16 2004-12-21 Cardiac Intelligence Corporation System and method for prioritizing multiple health disorders for use in automated patient care
US6827690B2 (en) 1999-11-16 2004-12-07 Cardiac Intelligence Corporation System and method for providing diagnosis and monitoring of myocardial ischemia for use in automated patient care
US6826425B2 (en) 1999-11-16 2004-11-30 Cardiac Intelligence Corporation System and method for providing diagnosis and monitoring of atrial fibrillation for use in automated patient care
US9232900B2 (en) 1999-11-16 2016-01-12 Cardiac Pacemakers, Inc. System and method for analyzing a patient status for congestive heart failure for use in automated patient care
US8874200B2 (en) 1999-11-16 2014-10-28 Cardiac Pacemakers, Inc. System and method for automated diagnosis of atrial fibrillation through remote monitoring
US6811537B2 (en) 1999-11-16 2004-11-02 Cardiac Intelligence Corporation System and method for providing diagnosis and monitoring of congestive heart failure for use in automated patient care
US6704595B2 (en) 1999-11-16 2004-03-09 Cardiac Intelligence Corporation Automated method for diagnosing and monitoring the outcomes of atrial fibrillation
US6694186B2 (en) 1999-11-16 2004-02-17 Cardiac Intelligence Corporation Automated collection and analysis patient care system for managing the pathophysiological outcomes of atrial fibrillation
US6440066B1 (en) 1999-11-16 2002-08-27 Cardiac Intelligence Corporation Automated collection and analysis patient care system and method for ordering and prioritizing multiple health disorders to identify an index disorder
US8942794B2 (en) 1999-11-16 2015-01-27 Cardiac Pacemakers, Inc. System and method for prioritizing medical conditions
US8888710B2 (en) 2004-02-19 2014-11-18 Cardiac Pacemakers, Inc. System and method for assessing cardiac performance through cardiac vibration monitoring
US8521288B2 (en) 2005-01-27 2013-08-27 Cardiac Pacemakers, Inc. Apparatus and method for temporary treatment of acute heart failure decompensation
US7386345B2 (en) 2005-01-27 2008-06-10 Cardiac Pacemakers, Inc. Apparatus and method for temporary treatment of acute heart failure decompensation

Also Published As

Publication number Publication date Type
EP0921842A4 (en) 1999-12-15 application
CA2251718A1 (en) 1997-10-30 application
EP0921842A1 (en) 1999-06-16 application
JP3325273B2 (en) 2002-09-17 grant
JP2000510005A (en) 2000-08-08 application
CA2251718C (en) 2001-07-10 grant

Similar Documents

Publication Publication Date Title
Miller et al. Effect of chronic pressure and volume overload on left heart volumes in subjects with congenital heart disease
Lamia et al. Echocardiographic prediction of volume responsiveness in critically ill patients with spontaneously breathing activity
Monnet et al. Passive leg raising predicts fluid responsiveness in the critically ill
Thomas et al. Hemodynamic changes in patients with acute: myocardial infarction
Grubb et al. Cerebral vasoconstriction during head-upright tilt-induced vasovagal syncope. A paradoxic and unexpected response.
Raev Which left ventricular function is impaired earlier in the evolution of diabetic cardiomyopathy?: an echocardiographic study of young type I diabetic patients
Diamond et al. Effect of coronary artery disease and acute myocardial infarction on left ventricular compliance in man
McKay et al. Instantaneous measurement of left and right ventricular stroke volume and pressure-volume relationships with an impedance catheter.
Shapiro et al. Left ventricular hypertrophy. Relation of structure to diastolic function in hypertension.
Reuter et al. Stroke volume variations for assessment of cardiac responsiveness to volume loading in mechanically ventilated patients after cardiac surgery
Sharma et al. Left ventricular angiography on exercise. A new method of assessing left ventricular function in ischaemic heart disease.
US5535753A (en) Apparatus and methods for the noninvasive measurement of cardiovascular system parameters
US5732710A (en) Method and device for stable impedance plethysmography
Nagueh et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy
Borlaug et al. Impact of arterial load and loading sequence on left ventricular tissue velocities in humans
Cotter et al. Accurate, noninvasive continuous monitoring of cardiac output by whole-body electrical bioimpedance
US6749567B2 (en) Noninvasive method of measuring physiologic parameters
Miller et al. Impedance cardiography
Keren et al. Evaluation of a noninvasive continuous cardiac output monitoring system based on thoracic bioreactance
US20090048497A1 (en) Dynamically variable filter
US5749369A (en) Method and device for stable impedance plethysmography
Jellema et al. Finger arterial versus intrabrachial pressure and continuous cardiac output during head-up tilt testing in healthy subjects
Jeremy et al. Relation between age, arterial distensibility, and aortic dilatation in the Marfan syndrome
Raval et al. Multicenter evaluation of noninvasive cardiac output measurement by bioreactance technique
US20060200033A1 (en) System, method and apparatus for measuring blood flow and blood volume

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1997922343

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 1997 538195

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2251718

Kind code of ref document: A

Format of ref document f/p: F

Ref document number: 2251718

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1997922343

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997922343

Country of ref document: EP